<SEC-DOCUMENT>0001824293-23-000102.txt : 20230424
<SEC-HEADER>0001824293-23-000102.hdr.sgml : 20230424
<ACCEPTANCE-DATETIME>20230424182939
ACCESSION NUMBER:		0001824293-23-000102
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20230421
FILED AS OF DATE:		20230424
DATE AS OF CHANGE:		20230424

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Chaturvedi Vipin
		CENTRAL INDEX KEY:			0001971423

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40034
		FILM NUMBER:		23841236

	MAIL ADDRESS:	
		STREET 1:		2223 AVIENDA DE LA PLAYA
		STREET 2:		SUITE 208
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GRI BIO, Inc.
		CENTRAL INDEX KEY:			0001824293
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				824369909
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		2223 AVENIDA DE LA PLAYA
		STREET 2:		SUITE 208
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		(619) 400-1171

	MAIL ADDRESS:	
		STREET 1:		2223 AVENIDA DE LA PLAYA
		STREET 2:		SUITE 208
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vallon Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20200910
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>wf-form4_168237536636728.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0407</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2023-04-21</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001824293</issuerCik>
        <issuerName>GRI BIO, Inc.</issuerName>
        <issuerTradingSymbol>GRI</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001971423</rptOwnerCik>
            <rptOwnerName>Chaturvedi Vipin</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O GRI BIO, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>2223 AVENIDA DE LA PLAYA, SUITE 208</rptOwnerStreet2>
            <rptOwnerCity>LA JOLLA</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>92037</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Scientific Officer</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2023-04-21</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>172189</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F1"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>172189</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable></derivativeTable>

    <footnotes>
        <footnote id="F1">Received in exchange for 4,600,000 shares of common stock of GRI Bio, Inc. (&quot;GRI&quot;), pursuant to the Agreement and Plan of Merger, dated December 13, 2022, by and among Vallon Pharmaceuticals, Inc. (the &quot;Company&quot;), Vallon Merger Sub, Inc. and GRI Bio, Inc. (the &quot;Merger&quot;). Per the terms of the Merger, each share of GRI common stock was converted into the right to receive 0.0374 shares of the Company's common stock. In connection with the Merger, the Company effected a reverse stock split of the Company's common stock at a ratio of 1-for-30 (the &quot;Reverse Split&quot;). Unless noted otherwise, all references to share amounts in this Form 4 reflect the Reverse Split.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Leanne Kelly, Attorney-in-Fact</signatureName>
        <signatureDate>2023-04-24</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
